// App-Quantinova.ai

: Role of mTORC1 and mTORC2 during Chronic Lymphocytic Leukaemia (CLL) Initiation and Progression

Researchers

Presenter

  • Natasha Malik

Principal Investigators

  • Karen Dunn

  • Owen Sansom

  • Alison M Michie

Medical Centers

  • Paul O?Gorman Leukaemia Research Centre, University of Glasgow, Glasgow, United Kingdom

  • University of Glasgow, Institute of Cancer Sciences, Glasgow, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chronic Lymphocytic Leukemia

Biomarkers

  • KIT Proto-Oncogene, Receptor Tyrosine Kinase

  • Serine/threonine-protein kinase mTOR

  • Red Blood Cells

Drug/Treatment

  • Rapacan

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved